Trevogrumab + Garetosmab — Clean Breakdown (Research Context) Trevogrumab and Garetosmab both target the same overall control system in the body: the myostatin/activin pathway, which regulates how muscle grows and how tissue repairs. Trevogrumab (anti-myostatin):This removes the body’s built-in “brake” on muscle growth. Myostatin normally limits how much muscle you can build. When you block it, muscle size can increase more easily.That said, studies show this effect is often incomplete on its own because the body compensates through other signals. - Amthor et al., 2007 — Myostatin knockout models show significant hypertrophy - Campbell et al., 2017 — Anti-myostatin therapies increase mass, but functional outcomes vary Garetosmab (anti-Activin A):This targets Activin A, which is more tied to fibrosis, inflammation, and misdirected tissue growth. Blocking it helps clean up the signaling environment so tissue repair happens more correctly. - Hatsell et al., 2015 — Activin A drives abnormal tissue formation in FOP - Upadhyay et al., 2017 — Activin signaling plays a key role in tissue remodeling and fibrosis Why they matter together: Myostatin and Activin A both signal through the ActRIIB receptor. If you only block myostatin, Activin can still limit results. So the idea is simple: - Trevogrumab → increases muscle growth potential - Garetosmab → reduces negative / fibrotic signaling Together, you’re not just pushing growth you’re also removing interference. Big picture: This is a more complete way to shift the body out of a catabolic (breakdown-limited) state and into a more favorable growth and repair environment. Still experimental, but mechanistically very relevant. In practical peptide frameworks, similar outcomes are approached more indirectly through GH signaling, repair peptides, and mitochondrial support just without directly blocking these pathways.